2011
DOI: 10.1016/j.bmcl.2010.12.124
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis, structure–activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
30
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 60 publications
(33 citation statements)
references
References 19 publications
2
30
0
1
Order By: Relevance
“…SKLB316 has been developed via computer-aided drug design, structural modification of benzothiazole-2-thiol derivatives [18,32], and de novo synthesis. In the present study, we investigated the activities of SKLB316 to inhibit colorectal and pancreatic cancer in vitro and in vivo and the possible mechanism.…”
Section: Discussionmentioning
confidence: 99%
“…SKLB316 has been developed via computer-aided drug design, structural modification of benzothiazole-2-thiol derivatives [18,32], and de novo synthesis. In the present study, we investigated the activities of SKLB316 to inhibit colorectal and pancreatic cancer in vitro and in vivo and the possible mechanism.…”
Section: Discussionmentioning
confidence: 99%
“…Compounds (90,91) exhibited good antitumor activities against the different types of human cancer cell lines in vitro, with IC 50 values ranging from 1.1 to 8.8 mM. The SAR study reveals that chloromethyl could improve significantly the antitumor activity of this series of BTA derivatives [130]. N-Fluoroalkyl-N'-benzothiazolyl ureas 92(aec) were synthesized by Luzina and Popov, studied their in vitro antiproliferative activities against the human diseaseoriented tumor cell lines MCF7 (breast), NCIeH460 (lung), and SF-268 (CNS).…”
Section: Other Bta-based Anticancer Agentsmentioning
confidence: 94%
“…SKLB-163) was developed via computer-aided drug design and de novo synthesis in our laboratory. Our data exhibited that SKLB-163 had good anticancer activities in vitro and in vivo (9,10). The molecular mechanism is involved as follows: SKLB-163 inhibited the upstream RhoGDIα protein and activated that c-Jun N-terminal kinase 1 signaling pathway that could contribute to the activation of caspase-3, decreased level of phosphorylated mitogen-activated protein kinase and AKT.…”
Section: Introductionmentioning
confidence: 79%
“…The route adapted for the synthesis of the SKLB-163 compound was performed as previously described (10). SKLB-163 was dissolved in dimethyl sulfoxide (DMSO) as a stock solution and was stored at 4˚C.…”
Section: Methodsmentioning
confidence: 99%